Year 2020 / Volume 112 / Number 7
Original
Vedolizumab response in inflammatory bowel disease. Two years of follow-up

555-558

DOI: 10.17235/reed.2020.7130/2020

Pilar del Pino Bellido, María Belvis Jiménez, Luisa Castro Laria, María Belén Maldonado Pérez, Antonia Sáez Díaz, Ángel Caunedo Álvarez, Federico Argüelles-Arias,

Abstract
Background: vedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab. Methods: this was a retrospective study of inflammatory bowel disease (IBD) patients who received vedolizumab between 2016 and 2019. Response and remission rates were analyzed at three, six, 12, 18 and 24 months after induction. Results: fifty-five patients were included. Clinical remission rates in CD and UC at three, six, 12, 18 and 24 months were 19.35 %, 26.67 %, 30.43 %, 30 %, 38.89 % and 29.17 %, 26.09 %, 19.05 %, 26.67 % and 20 %, respectively. Conclusions: vedolizumab is effective for induction and maintenance of clinical remission, both in Crohn’s disease and ulcerative colitis.
Share Button
New comment
Comments
No comments for this article
Related articles

Review

Immunotherapy in hepatocellular carcinoma

DOI: 10.17235/reed.2022.8876/2022

Editorial

Inflammatory bowel disease – Newer models of care

DOI: 10.17235/reed.2019.6495/2019

Citation tools
del Pino Bellido P, Belvis Jiménez M, Castro Laria L, Maldonado Pérez M, Sáez Díaz A, Caunedo Álvarez Á, et all. Vedolizumab response in inflammatory bowel disease. Two years of follow-up. 7130/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1016 visits.
This article has been downloaded 227 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 13/04/2020

Accepted: 04/06/2020

Online First: 24/06/2020

Published: 08/07/2020

Article revision time: 50 days

Article Online First time: 72 days

Article editing time: 86 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology